Akums Drugs and Pharmaceuticals Ltd. Shares of were locked in the lower circuit of 5 percent on Thursday, November 14. The stock has seen two 10 per cent lower circuits and two 5 per cent lower circuits in the last four days.
The stock has declined 35 percent in the last 10 sessions and has fallen in 10 out of the last 11 trading sessions.
Delhi-based contract development and manufacturing organization (CDMO) has reported 16 per cent year-on-year (YoY) rise in adjusted net profit at ₹66.7 crore. Revenue declined by 11.9 per cent to ₹1,046 crore due to lower active pharmaceutical ingredient (API) prices and demand fluctuations.
Adjusted EBITDA stood at ₹134.7 crore, a decline of 28% from the previous quarter, while the company’s adjusted EBITDA margin stood at 12.9%. Exports contribute about 5 percent of the company’s total revenue. Aakums is a pharmaceutical CDMO that offers a wide range of pharmaceutical products and services in India and abroad. The company has the largest capacity in the country. Its capacity utilization rate is 40% and can be increased to 60%.
The stock of the pharmaceutical company has crossed its previous low of ₹612.70 on November 13, 2024. Shares of Akums Drugs and Pharma are currently in the lower circuit of 5% at ₹582.10. The stock is now down 14% from its IPO price of ₹679.
Disclaimer: This information is for informational purposes only and should not be construed as investment advice. It is recommended to consult a financial advisor before making investment decisions.